Edesa Biotech VE/BAIIA
Quel est le VE/BAIIA de Edesa Biotech?
Le VE/BAIIA de Edesa Biotech, Inc. est N/A
Quelle est la définition de VE/BAIIA?
VE/BAIIA est la valeur de l’entreprise divisée par le bénéfice avant intérêts, impôts, dépréciations et amortissements. Il s'agit d'une mesure du coût d'une action et est plus souvent valable pour des comparaisons entre sociétés que le ratio cours / bénéfice. Il mesure le prix (sous forme de valeur d'entreprise) qu'un investisseur paie au profit des flux de trésorerie de l'entreprise (sous forme de BAIIA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
VE/BAIIA des entreprises dans Health Care secteur sur NASDAQ par rapport à Edesa Biotech
Que fait Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Entreprises avec ve/baiia similaire à Edesa Biotech
- Bambuser AB (publ) a VE/BAIIA de N/A
- Nevada Metals a VE/BAIIA de N/A
- Elys Game Technology a VE/BAIIA de N/A
- Velodyne Lidar a VE/BAIIA de N/A
- Blue Sky Alternative Investments a VE/BAIIA de N/A
- Arix Bioscience plc a VE/BAIIA de N/A
- Edesa Biotech a VE/BAIIA de N/A
- Shenzhen Neptunus Interlong Bio-technique a VE/BAIIA de N/A
- Baumot AG a VE/BAIIA de N/A
- Discovery Harbour Resources a VE/BAIIA de N/A
- Guardion Health Sciences Inc a VE/BAIIA de N/A
- Taronis Fuels a VE/BAIIA de N/A
- DQ Entertainment (International) a VE/BAIIA de N/A